You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition
|
|---|---|
| Published in |
Molecular and Clinical Oncology, May 2018
|
| DOI | 10.3892/mco.2018.1634 |
| Pubmed ID | |
| Authors |
Carlo Capalbo, Francesca Belardinilli, Marco Filetti, Claudia Parisi, Marialaura Petroni, Valeria Colicchia, Alessandra Tessitore, Matteo Santoni, Anna Coppa, Giuseppe Giannini, Paolo Marchetti |
| Abstract |
Cutaneous squamous cell carcinoma (cSCC) is the second most common type of non-melanoma skin cancer. Platinum-based regimens have been an integral part of palliative care for patients with locally advanced or metastatic disease. There is no evidence of efficacy for later lines of chemotherapy and no targeted therapy has been introduced as 'standard of care'. Here we report on the case of an elderly cSCC patient, resistant to conventional therapy, however successfully treated with anti-epidermal growth factor receptor (EGFR) agent (Cetuximab) in addition to a daily dose of Curcumin phospholipid. The patient responded to treatment and experienced no recurrence for 11 months with only minor skin-related toxicity. To our knowledge, this is the first report of clinical evidence that an anti EGFR targeted therapy with a daily oral dose of Curcumin phospholipid is well tolerated and results in a highly effective disease control in a heavily pretreated cSCC patient. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 17% |
| Researcher | 3 | 13% |
| Student > Postgraduate | 2 | 9% |
| Student > Master | 2 | 9% |
| Student > Bachelor | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 11 | 48% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 17% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Veterinary Science and Veterinary Medicine | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Other | 2 | 9% |
| Unknown | 12 | 52% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 July 2018.
All research outputs
#17,982,872
of 23,094,276 outputs
Outputs from Molecular and Clinical Oncology
#317
of 740 outputs
Outputs of similar age
#238,874
of 330,254 outputs
Outputs of similar age from Molecular and Clinical Oncology
#6
of 14 outputs
Altmetric has tracked 23,094,276 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 740 research outputs from this source. They receive a mean Attention Score of 2.0. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,254 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.